Members

We are the developer of an innovative technology for the production of a completely new highly effective active substance. These regenerating products are extremely effective in treatment of liver cirrhosis of various etiologies previously officially considered incurable (ascites goes away after 15 days, cirrhosis changes into fibrosis after 30-50 days, the period of complete hepatic regeneration is about 4 months). They are also effective against genital herpes virus (4-6 months), effective against hepatitis of various etiologies, including such as B, C, D ( viral load is reduced by half every 26 days, after a course of therapy, the virus is not detected in the blood, the patient ceases to be a virus carrier), drugs restore the liver in case of fatty hepatosis, pulmonary tuberculosis including MDR TB/ XDR TB (after 26 days an active form of stage 4 changes into stage 2-3 of latent form), lymphosarcoma, fibroma, myoma and pyelonephritis. The drugs prevent diabetic foot gangrene extremities. After the therapy patients no longer need previously recommended heart bypass surgery. The drug restores the function of the pancreas, and gives a complete restoration of long-term erectile dysfunction. The condition of patients with Alzheimer disease, Down's syndrome, encephalopathy, encephalitis and other diseases improves significantly without any side effects. The drugs have a strong antifibrotic effect, they dissolve scars on heart after myocardial infarction. Heart tissue completely regenerates within 6 months. This is only what we have studied so far.  We have strong assumptions that our medications can also effectively affect the activity of the COVID-19 coronavirus, as well as other viruses and infections. We are interested in partners and research of our drugs.

I have broad experience of interdisciplinary work, from computing and mathematics in my PhD and post-doctoral work, to psychology, sociology, applied philosophy and communications studies in considering the social, legal and ethical impacts of computer and communications technology. I recently also starting collaborating with a film studies scholar on the impact of films and television on public perception of social issues such as security, surveillance and AI. I have published work relating to copyright, security, surveillance, privacy, responsible research and innovation, ubiquitous computing (aka Internet of Things), medical technology. I am interested in too many things.

A long-time journalist with medical background, I have served as program communication officer and consultant for Communication for Development (C4D) at UNICEF Indonesia. With two decades of international experience in business management, government and public relations, education / training, and media, I have broadened my views on socio-political, health, economic and development trends and issues through works in non-profit organizations such as Australia AID, and Germany’s Particip GmbH. Formerly acted as Director for Marketing & Public Relations in a private university in Jakarta, I gained MA in Journalism from University of Technology Sydney (UTS), Australia. My journalistic background in Australia and Indonesia has been enriched, for instance, by leadership experience when acting as the Branch Development head of Indonesian Public Relations Association.